Wednesday, 20 Mar 2019

You are here

Type I Interferon Drives Photosensitivity in Cutaneous Lupus

Kahlenberg and coworkers have reported in ARD that interferon kappa (IFN-κ) is a key regulator of type I interferon (IFN) photosensitive responses in patients with cutaneous lupus erythematosus (CLE).

They analyzed mRNA expression of type I IFN gene expression by microarrays of biopsied CLE lesions and healthy control skin. They also examined gene expression in cultured keratinocytes, fibroblasts and endothelial cells IFNK knock-out keratinocytes generated using CRISPR/Cas9. 

They discovered that IFNK is one of two type I IFNs significantly increased (1.5-fold change) in lesional CLE skin.

Type I IFN responses were enriched in keratinocytes, but not in fibroblast or endothelial cells, and that epithelial-derived IFN-κ is responsible for maintaining baseline type I IFN responses in healthy skin.

Increased levels of IFN-κ seen in SLE can amplify and accelerate responsiveness of epithelia to IFN-α and increase keratinocyte sensitivity to UV irradiation.

IFN-κ is a critical IFN in CLE pathology via promotion of enhanced IFN responses and photosensitivity and could therefore be a potential novel treatment target.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Cyclosporin and IVIG Effective in Kawasaki's Disease

A Lancet study has shown that adding cyclosporin to intravenous immunoglobulin (IVIG) Kawasaki disease patients, who were predicted to be resistant to IVIG, was both safe and effective in averting severe coronary artery outcomes.

Brazilian Guidelines for Systemic Autoimmune Myopathies

The Myopathy Committee of the Brazilian Society of Rheumatology (BSR) has put forward recommendations for the management of patients with systemic autoimmune myopathies (SAM).

The challenge has been that there is a paucity of effective controlled clinical trials, and hence, glucocorticoids (GC) have played a first-line and prominent role in the treatment of SAM.

EULAR Consensus Guidelines for Juvenile Localized Scleroderma

A EULAR international committee of 15 experts in pediatric rheumatology have established consensus-based recommendations for the management of juvenile localised scleroderma (JLS).

JLS is an uncommon disorder that is commonly seen by pediatric and adult rheumatologists. Evidence-based guidelines are sparse and management is mostly based on physicians’ experience.

2018 Swedish Guidelines for Giant Cell Arteritis Treatment

The Swedish Society of Rheumatology has developed evidence-based guidelines for the management of giant cell arteritis (GCA) with a focus on the appropriate use of corticosteroids and tocilizumab. 

Congenital Heart Block: Dangers Ahead

Children of autoantibody-positive mothers who were born with congenital heart block were at high risk for developing later cardiovascular and autoimmune disorders, as were their siblings, Swedish researchers reported.